In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
Several CRISPR-Cas9 orthologues have been used for genome editing. Here, we present the smallest Cas9 orthologue characterized to date, derived from Campylobacter jejuni (CjCas9), for efficient genome editing in vivo . After determining protospacer-adjacent motif (PAM) sequences and optimizing single-guide RNA (sgRNA) length, we package the CjCas9 gene, its sgRNA sequence, and a marker gene in an all-in-one adeno-associated virus (AAV) vector and produce the resulting virus at a high titer. CjCas9 is highly specific, cleaving only a limited number of sites in the human or mouse genome. CjCas9, delivered via AAV, induces targeted mutations at high frequencies in mouse muscle cells or retinal pigment epithelium (RPE) cells. Furthermore, CjCas9 targeted to the Vegfa or Hif1a gene in RPE cells reduces the size of laser-induced choroidal neovascularization, suggesting that in vivo genome editing with CjCas9 is a new option for the treatment of age-related macular degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Smaller genome editing proteins, such as the S. aureus Cas9, C. jejuni Cas9 and newly identified CRISPR-Cas enzymes, may circumvent this issue 23,61-65 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The downregulation was linked to a decrease in spot size on morphology of the laser-induced choroidal neovascularization (wet AMD model) but not on retinal function measured by electroretinogram (ERG) [221].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [221]
The cited source says what the claim attributes to it.
In the citing paper
“Fonfara et al. previously reported the optimal in vitro PAM site for CjCas9 to be 5′-NNNNACA”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“In February 2017, Kim et al. presented efficient in vivo genome editing using the smallest Cas9 orthologue (2.95 kb) that has been characterized as of February 2017: Campylobacter jejuni (CjCas9) [72].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“In February 2017, Kim et al. presented efficient in vivo genome editing using the smallest Cas9 orthologue (2.95 kb) that has been characterized as of February 2017: Campylobacter jejuni (CjCas9) [72].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [72]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
Self-citationRNA-programmed genome editing in human cells
Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., & Doudna, J. (2013) · eLife · doi:10.7554/elife.00471 · Cited by 2,098
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2507 · Cited by 1,863
Self-citationStructural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease
Anders, C., Niewoehner, O., Duerst, A., & Jinek, M. (2014) · Nature · doi:10.1038/nature13579 · Cited by 1,323
Cited by
Items 401–500 of 730
In vivo application of base and prime editing to treat inherited retinal diseases
Jo, D. H., Bae, S., Kim, S., Kim, J., & Kim, J. H. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101132 · Cited by 17
Self-citationGenome and transcriptome engineering by compact and versatile CRISPR-Cas systems
Aquino‐Jarquín, G. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103793 · Cited by 15
CRISPR-Cas Genome Surgery in Ophthalmology
DiCarlo, J. E., Sengillo, J. D., Justus, S., Cabral, T., Tsang, S. H., & Mahajan, V. B. (2017) · Translational Vision Science & Technology · doi:10.1167/tvst.6.3.13 · Cited by 17
Active fusions of Cas9 orthologs
Josipović, G., Zoldoš, V., & Vojta, A. (2019) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2019.05.306 · Cited by 15
Advances and Obstacles in Homology-Mediated Gene Editing of Hematopoietic Stem Cells
Salisbury-Ruf, C. T., & Larochelle, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030513 · Cited by 15
Application of CRISPR/Cas System in the Metabolic Engineering of Small Molecules
Singh, R., Chandel, S., Ghosh, A., Dey, D., Chakravarti, R., Roy, S., Ravichandiran, V., & Ghosh, D. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00310-1 · Cited by 15
Delivery of nVEGFi using AAV8 for the treatment of neovascular age-related macular degeneration
She, K., Su, J., Wang, Q., Liu, Y., Zhong, X., Jin, X., Zhao, Q., Xiao, J., Li, R., Deng, H., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.002 · Cited by 16
Chen, H., Durinck, S., Patel, H., Foreman, O., Mesh, K., Eastham, J., Caothien, R. H., Newman, R. J., Roose‐Girma, M., Darmanis, S., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.10.016 · Cited by 15
AcrIIC4 inhibits type II-C Cas9 by preventing R-loop formation
Sun, W. D., Cheng, Z., Wang, J., Yang, J., Li, X., Wang, J., Chen, M., Yang, X., Sheng, G., Lou, J., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303675120 · Cited by 16
Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing
Aslesh, T., Erkut, E. J. N., & Yokota, T. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1872539 · Cited by 16
Mutation-independent therapies for retinal diseases: focus on gene-based approaches
Carrella, S., Indrieri, A., Franco, B., & Banfi, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.588234 · Cited by 14
“In particular, an AAV-CRISPR/Cas9 approach was recently used, in a mutationindependent manner, to inactivate VEGF-A and vascular endothelial growth factor receptor-2 in RPE cells, thus abrogating angiogenesis (Huang et al., 2017; Kim et al., 2017a,b).”
MethodSimons, E. J., & Trapani, I. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.126 · Cited by 14
“Both identification of Cas9 orthologs with reduced size, 37–39 which allows packaging of both the Cas endonuclease and gRNA expression cassette in a single vector, and further development in delivery vehicles, including nonviral vector-based approaches, are actively ongoing to overcome this…”
CRISPR/Cas9 genome surgery for retinal diseases
Xu, C. L., Park, K. S., & Tsang, S. H. (2018) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2018.05.001 · Cited by 14
Mehnath, S. (2025) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaf127 · Cited by 15
Gene editing therapy for cardiovascular diseases
Wu, X., Yang, J., Zhang, J., & Song, Y. (2024) · MedComm · doi:10.1002/mco2.639 · Cited by 17
Ma, Y., Tan, Y., Li, J., Xiang, Q., Liu, S., Jin, X., Shao, S., Geng, W., Zhu, L., & Yang, D. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c03206 · Cited by 14
Chang, Y. J., Bae, J., Zhao, Y., Lee, G. S., Han, J. P., Lee, Y. H., Koo, O. J., Seo, S.-M., Choi, Y., & Yeom, S. C. (2020) · Journal of Veterinary Science · doi:10.4142/jvs.2020.21.e26 · Cited by 14
Two high-fidelity variants: efSaCas9 and SaCas9-HF, which one is better?
Lv, J., Xi, H., Lv, X., Zhou, Y., Wang, J., Chen, H., Yan, T., Jin, J., Zhao, J., Gu, F., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00319-4 · Cited by 14
Development and expansion of the CRISPR/Cas9 toolboxes for powerful genome engineering in yeast
Guang, C., Lin, Z., & Shi, S. (2022) · Enzyme and Microbial Technology · doi:10.1016/j.enzmictec.2022.110056 · Cited by 15
CRISPR‐Cas system: Toward a more efficient technology for genome editing and beyond
Ahmadzadeh, V., Farajnia, S., Baghban, R., Rahbarnia, L., & Zarredar, H. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29140 · Cited by 14
Genome Surgery and Gene Therapy in Retinal Disorders.
Chan, L., Mahajan, V. B., & Tsang, S. H. (2017) · PubMed Central · Cited by 16
Ren, Z., Zhou, J., Yang, D., Guo, Y., Zhang, J., Xu, J., & Chen, Y. E. (2026) · Cells · doi:10.3390/cells15020134 · Cited by 15
Prime Editing: Mechanistic Insights and DNA Repair Modulation
Mentani, A., Maresca, M., & Shiriaeva, A. (2025) · Cells · doi:10.3390/cells14040277 · Cited by 15
Engineering adeno-associated viral vectors for CRISPR/Cas based in vivo therapeutic genome editing
Moyo, B., Brown, L. B. C., Khondaker, I., & Bao, G. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123314 · Cited by 13
Gene Editing for Duchenne Muscular Dystrophy: From Experimental Models to Emerging Therapies
Haque, U. S., & Yokota, T. (2025) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s495536 · Cited by 23
In vivo delivery systems for CRISPR genome editing: Viral and non-viral carriers
Lee, Y., Kim, B., Lee, D., Cheon, S. Y., Lim, S. G., Kim, Y., & Koo, H. (2025) · Applied Physics Reviews · doi:10.1063/5.0228874 · Cited by 13
Modeling Non-Alcoholic Fatty Liver Disease (NAFLD) Using “Good-Fit” Genome-Editing Tools
Kim, U., Kim, N., & Shin, H. Y. (2020) · Cells · doi:10.3390/cells9122572 · Cited by 13
Zhi, L., Su, X., Yin, M., Zhang, Z., Lü, H., Niu, Z., Guo, C., Zhu, W., & Zhang, X. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104436 · Cited by 15
CRISPR/Cas systems usher in a new era of disease treatment and diagnosis
Li, R., Wang, Q., She, K., Lu, F., & Yang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00095-y · Cited by 14
A new compact adenine base editor generated through deletion of HNH and REC2 domain of SpCas9
Qian, Y., Wang, D., Niu, W., Zhao, D., Li, J., Liu, Z., Gao, X., Han, Y., Lai, L., & Li, Z. (2023) · BMC Biology · doi:10.1186/s12915-023-01644-9 · Cited by 14
From Bench to Bed: The Current Genome Editing Therapies for Glaucoma
He, M., Rong, R., Ji, D., & Xia, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.879957 · Cited by 14
CRISPR-Cas Technology: A Genome-Editing Powerhouse for Molecular Plant Breeding
Mohan, C., Satish, L., Muthubharathi, B. C., Selvarajan, D., Easterling, M., & Yau, Y. (2022) · Springer eBooks · doi:10.1007/978-981-16-9001-3_32 · Cited by 15
Application of CRISPR-Cas9 in eye disease
Wu, W., Tang, L., D'Amore, P. A., & Lei, H. (2017) · Experimental Eye Research · doi:10.1016/j.exer.2017.06.007 · Cited by 16
Integrated design, execution, and analysis of arrayed and pooled CRISPR genome editing experimentsPreprint
Canver, M. C., Haeussler, M., Bauer, D. E., Orkin, S. H., Sanjana, N. E., Shalem, O., Yuan, G., Zhang, F., Concordet, J., & Pinello, L. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/125245 · Cited by 13
The history, use, and challenges of therapeutic somatic cell and germline gene editing
Ryu, J., Adashi, E. Y., & Hennebold, J. D. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.02.040 · Cited by 13
Evaluation and prediction of guide RNA activities in genome-editing tools
Kim, H. K., & Kim, S. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00352-z · Cited by 16
Self-citationMegagiannis, P., Suresh, R., Rouleau, G. A., & Zhou, Y. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114562 · Cited by 12
Transgene-free genome editing and RNAi ectopic application in fruit trees: Potential and limitations
Gouthu, S., Mandelli, C., Eubanks, B. A., & Deluc, L. G. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2022.979742 · Cited by 14
Directed evolution studies of a thermophilic Type II-C Cas9
Hand, T. H., Das, A., & Li, H. (2018) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2018.10.029 · Cited by 13
Comparison of DNA targeting CRISPR editors in human cells
Huang, H., Lv, W., Li, J., Huang, G., Tan, Z., Hu, Y., Ma, S., Zhang, X., Huang, L., & Lin, Y. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00958-z · Cited by 12
Genome Editing in Retinal Diseases using CRISPR Technology
Yiu, G. C. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.09.015 · Cited by 12
From Bench to Bedside—Delivering Gene Therapy for Leber Hereditary Optic Neuropathy
Chen, B. S., & Yu‐Wai‐Man, P. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041282 · Cited by 14
Methods for detecting off-target effects of CRISPR/Cas9
Xu, Y., Zhou, S., Wang, L.-Y., Zhang, R., Li, K., Qian, Z., & Li, X. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108750 · Cited by 13
CRISPR-Based Transcriptional Regulation: Technologies, Applications, and Future Directions
Srinivasa, M. A., & Escobar, M. (2025) · DNA · doi:10.3390/dna5040057 · Cited by 15
Recent developments with advancing gene therapy to treat chronic infection with hepatitis B virus
Maepa, M. B., Jacobs, R., van den Berg, F. T., & Arbuthnot, P. B. (2020) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000623 · Cited by 12
Hall, J. C., Paull, D. J., Pébay, A., & Lidgerwood, G. E. (2022) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14128 · Cited by 12
Shamsnajafabadi, H., Kaukonen, M. K., Bellingrath, J.-S., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2024) · Genes · doi:10.3390/genes15050625 · Cited by 11
CRISPR/Cas-based devices for mammalian synthetic biology
Kim, T., & Lu, T. K. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.04.015 · Cited by 11
Postnatal therapeutic approaches in genetic neurodevelopmental disorders
Levy, G., & Barak, B. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.293133 · Cited by 12
CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals
Karapurkar, J. K., Antao, A. M., Kim, K.-S., & Ramakrishna, S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.018 · Cited by 14
Self-citationLi, Y., & Zhou, L. (2021) · BioEssays · doi:10.1002/bies.202100086 · Cited by 11
The origin of unwanted editing byproducts in gene editing
Yin, J., & Hu, J. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022056 · Cited by 12
Li, Z.-F., & Wu, N. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.911429 · Cited by 11
Precise Gene Knock‐In Tools with Minimized Risk of DSBs: A Trend for Gene Manipulation
Liu, Y. H., Kong, J., Liu, G., Li, Z., & Xiao, Y. (2024) · Advanced Science · doi:10.1002/advs.202401797 · Cited by 13
CRISPR beyond: harnessing compact RNA-guided endonucleases for enhanced genome editing
Wang, F., Ma, S., Zhang, S., Ji, Q., & Hu, C. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2566-8 · Cited by 11
Attaining the Promise of Geminivirus-Based Vectors in Plant Genome Editing
Mahmood, M. A., Sajjad, M. W., Imran, I., Naqvi, R. Z., Amin, I. U., Shafiq, M., Aslam, M. Q., & Mansoor, S. (2025) · Viruses · doi:10.3390/v17050631 · Cited by 10
Bindal, G., & Rath, D. (2025) · Synthetic biology and engineering · doi:10.70322/sbe.2025.10014 · Cited by 15
Applying CRISPR-Cas9 screens to dissect hematological malignancies
Iyer, D. N., Schimmer, A. D., & Chang, H. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008966 · Cited by 10
Efficient prioritization of CRISPR screen hits by accounting for targeting efficiency of guide RNA
Park, B.-S., Jeon, H., Chi, S., & Kim, T. (2023) · BMC Biology · doi:10.1186/s12915-023-01536-y · Cited by 11
Alexander, L. M., Goltsman, D. S. A., Liu, J., Lin, J., Temoche-Diaz, M. M., Laperriere, S. M., Neerincx, A., Bednarski, C., Knyphausen, P., Cohnen, A., et al. (2023) · The CRISPR Journal · doi:10.1089/crispr.2022.0090 · Cited by 11
Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics
Hu, J., & Huang, A. (2023) · Virologica Sinica · doi:10.1016/j.virs.2023.12.005 · Cited by 11
Tackling hepatitis B Virus with CRISPR/Cas9: advances, challenges, and delivery strategies
Nair, D. M., Vajravelu, L. K., Thulukanam, J., Panneerselvam, V. P., Vimala, P. B., & Lathakumari, R. H. (2024) · Virus Genes · doi:10.1007/s11262-024-02105-3 · Cited by 13
Delivery Methods, Resources and Design Tools in CRISPR/Cas
Aslam, M. A., Hammad, M., Ahmad, A., Altenbuchner, J., & Ali, H. (2021) · Springer eBooks · doi:10.1007/978-981-15-7142-8_3 · Cited by 17
Exploiting DNA Endonucleases to Advance Mechanisms of DNA Repair
Thompson, M. K., Sobol, R. W., & Prakash, A. (2021) · Biology · doi:10.3390/biology10060530 · Cited by 12
CRISPR: a promising tool for lipid physiology and therapeutics
Furgurson, M. N., & Lagor, W. R. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000591 · Cited by 10
Targeted gene disruption by CRISPR/xCas9 system in Drosophila melanogaster
Ni, X., Zhou, Z., Huang, J., & Qiao, X. (2020) · Archives of Insect Biochemistry and Physiology · doi:10.1002/arch.21662 · Cited by 12
Promoter Orientation within an AAV-CRISPR Vector Affects Cas9 Expression and Gene Editing Efficiency
Fry, L. E., Peddle, C. F., Stevanovic, M., Barnard, A. R., McClements, M. E., & MacLaren, R. E. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0021 · Cited by 11
CRISPR Technology: Transforming the Future of Medicine and Diagnostics
Iyer, K. A., Tenchov, R., Diaz, L. M. L., Jain, P., Thite, T., Deng, Y., & Zhou, Q. A. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00480 · Cited by 13
Jiang, F., Zhang, C., Liu, W., Liu, F., Huang, H., Tan, Y. F., & Qin, B. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1301915 · Cited by 9
Sun, L., Zhang, T., Lan, X., Zhang, N., Wang, R., Ma, S., Zhao, P., & Xia, Q. (2024) · Insects · doi:10.3390/insects15040241 · Cited by 10
Exploitation of enhanced prime editing for blocking aberrant angiogenesis
Huang, X., Wu, W., Qi, H., Yan, X., Dong, L., Yang, Y., Zhang, Q., Ma, G., Zhang, G., & Lei, H. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.07.006 · Cited by 10
Zhang, C., Kang, G., Liu, X., Zhao, S., Yuan, S., Li, L., Yang, Y., Wang, F., Zhang, X., & Yang, J. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.618385 · Cited by 11
CRISPR/Cas: The New Frontier in Plant Improvement
Maximiano, M. R., & Franco, O. L. (2022) · ACS Agricultural Science & Technology · doi:10.1021/acsagscitech.1c00279 · Cited by 12
Rapid repair of human disease-specific single-nucleotide variants by One-SHOT genome editing
Yokouchi, Y., Suzuki, S., Ohtsuki, N., Yamamoto, K., Noguchi, S., Soejima, Y., Goto, M., Ishioka, K., Nakamura, I., Suzuki, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-70401-7 · Cited by 10
NmeCas9 is an intrinsically high-fidelity genome editing platformPreprint
Amrani, N., Gao, X. D., Liu, P., Edraki, A., Mir, A., Ibraheim, R., Gupta, A., Sasaki, K. E., Wu, T., Donohoue, P. D., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/172650 · Cited by 9
Enzyme miniaturization: Revolutionizing future biocatalysts
Ding, N., Jiang, Y., Lee, S., Cheng, Z., Ran, X., Ding, Y., Ge, R., Zhang, Y., & Yang, Z. J. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108598 · Cited by 9
Zhang, H., Li, Y., Li, J., Li, X., & Li, T. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111405 · Cited by 9
Toward In Vivo Gene Therapy Using CRISPR
Skipper, K. A., & Mikkelsen, J. G. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9170-9_18 · Cited by 8
Emerging CRISPR Therapies for Precision Gene Editing and Modulation in the Cardiovascular Clinic
Legere, N., & Hinson, J. T. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02125-3 · Cited by 8
Zhang, N., Heruth, D. P., Wu, W., Zhang, L. Q., Nsumu, M., Shortt, K., Li, K., Jiang, X., Wang, B., Friesen, C. A., et al. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0303-1 · Cited by 8
Rodríguez-Polo, I., & Behr, R. (2022) · Genes · doi:10.3390/genes13061093 · Cited by 8
New CRISPR Tools to Correct Pathogenic Mutations in Usher Syndrome
Major, L., McClements, M. E., & MacLaren, R. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911669 · Cited by 8
Single Molecule FRET Analysis of CRISPR Cas9 Single Guide RNA Folding Dynamics
Okafor, I. C., & Ha, T. (2022) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c05428 · Cited by 8
CRISPR technology in human diseases
Feng, Q., Li, Q., Zhou, H., Wang, Z., Lin, C., Jiang, Z., Liu, T., & Wang, D. (2024) · MedComm · doi:10.1002/mco2.672 · Cited by 11
Rationally designed Campylobacter jejuni Cas9 enables efficient gene activation and base editing
Chen, Y., Kang, R., Jiang, Y., Zheng, Q., Yang, Y., Liu, J., Wu, G., Zhao, W., Li, Z., Peng, C., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102366 · Cited by 8
How are genes modified? Crossbreeding, mutagenesis, and CRISPR-Cas9
Lemay, M.-L., & Moineau, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817240-7.00003-6 · Cited by 9
CRISPR/Cas-Based Insect Resistance in Crops
Zahoor, M. K., Ahmad, A., Zahoor, M. A., Majeed, H. N., Zulhussnain, M., & Ranian, K. (2021) · Springer eBooks · doi:10.1007/978-981-15-7142-8_4 · Cited by 10
Get ready for the CRISPR/Cas system: A beginner's guide to the engineering and design of guide RNAs
Ma, S., Lv, J., Feng, Z., Rong, Z., & Lin, Y. (2021) · The Journal of Gene Medicine · doi:10.1002/jgm.3377 · Cited by 8
Hu, S., Chen, Y., Xie, D., Xu, K., Fu, Y., Chi, W., Liu, H., & Huang, J. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1383 · Cited by 10
CRISPR/Cas9 System and its Research Progress in Gene Therapy
Liu, W., Yang, C., Liu, Y., & Jiang, G. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666191014103711 · Cited by 8
CRISPR-Cas technologies: Emerging tools from research to clinical application
Hyeon, H., Hwang, S., Luo, Y., Shin, E., Yeom, J., Kim, H., Ryu, M., & Lee, K. (2025) · The Journal of Microbiology · doi:10.71150/jm.2504012 · Cited by 7
Self-citationRemoval of the GAA repeat in the heart of a Friedreich’s ataxia mouse model using CjCas9
Yaméogo, P., Gérard, C., Majeau, N., & Tremblay, J. P. (2023) · Gene Therapy · doi:10.1038/s41434-023-00387-0 · Cited by 9
Detailed Insight into Various Classes of the CRISPR/Cas System to Develop Future Crops
Thakur, N., Lakhani, H., & Tiwari, S. (2024) · Springer eBooks · doi:10.1007/978-981-99-8529-6_9 · Cited by 11
Zeng, L., Wei, Y., Qiu, Y., Bi, R., Peng, H., Hu, B., & Li, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s521960 · Cited by 8
AAV-CRISPR Persistence in the Eye of the Beholder
Recchia, A. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.007 · Cited by 7
Basic and Clinical Application of Adeno-Associated Virus–Mediated Genome Editing
He, X., Xie, H., Liu, X., & Gu, F. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.190 · Cited by 7
Genome Editing in Zebrafish by ScCas9 Recognizing NNG PAM
Liu, Y., Liang, F., Dong, Z., Li, S., Ye, J., & Qin, W. (2021) · Cells · doi:10.3390/cells10082099 · Cited by 7
Genome Editing of Pik3cd Impedes Abnormal Retinal Angiogenesis
Wu, W., Ma, G., Qi, H., Dong, L., Chen, F., Wang, Y., Mao, X., Guo, X., Cui, J. Z., Matsubara, J. A., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.079 · Cited by 8
CRISPR-Mediated Base Editing: Promises and Challenges for a Viable Oncotherapy Strategy
Huang, L., Yang, C., Chen, Y., Deng, H., Liao, Z., & Xiao, H. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.045 · Cited by 9
Croteau, F. R., Rousseau, G. M., & Moineau, S. (2018) · médecine/sciences · doi:10.1051/medsci/2018215 · Cited by 7
Metadata
- Authors
- Kim, E., Koo, T., Park, S. W., Kim, D., Kim, K., Cho, H.-Y., Song, D. W., Lee, K. J., Jung, M. H., Kim, S., Kim, J. H., Kim, J. H., & Kim, J.-S.
- Affiliations
- Institute for Basic Science (KR)
- Seoul National University (KR)
- ToolGen (South Korea) (KR)
- Corresponding author
- Kim, Jeong Hun
- ORCID
- Venue
- Nature Communications
- Published
- 2017-02-21
- Volume
- 8
- Issue
- 1
- Pages
- 14500-14500
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5473640
- OpenAlex
- W2590764628
- Cited by
- 715
- References
- 38
- Citations by year
- 2026: 24 · 2025: 68 · 2024: 68 · 2023: 81 · 2022: 114 · 2021: 94 · 2020: 87 · 2019: 77 · 2018: 66 · 2017: 36
- FWCI
- 29.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- National Research Foundation (NRF-2015M3A9E6028949)
- Ministry of Science, ICT and Future Planning (NRF-2015M3A9E6028949, IBS-R021-D1, 2015M3A9E6028949)
- Korea Health Industry Development Institute (HI16C0426)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- in vivo gene editing, adeno-associated virus vectors, single guide RNA, protospacer adjacent motif, retinal pigment epithelium, choroidal neovascularization, age-related macular degeneration, VEGF-A, HIF1A, targeted mutagenesis
- MeSH terms
- Gene Editing, Dependovirus, Animals, Bacterial Proteins, Cells, Cultured, Endonucleases, Humans, Male, Mice, Inbred C57BL, Campylobacter jejuni, Choroidal Neovascularization, Vascular Endothelial Growth Factor A, Retinal Pigment Epithelium, HEK293 Cells, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.